Xilio Therapeutics (XLO) Assets Average (2021 - 2026)

Xilio Therapeutics has disclosed Assets Average across 6 years of filings, most recently posting $159.1 million for Q1 2026.

• Assets Average for Q1 2026 came in at $159.1 million, up 82.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $159.1 million (up 82.03% YoY), and the FY2025 annual result was $112.9 million, up 71.03% from the prior year.
• Assets Average came in at $159.1 million for Q1 2026 at Xilio Therapeutics, up from $144.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $207.2 million in Q1 2022 to a low of $69.4 million in Q4 2023.
• The 5-year median for Assets Average is $118.8 million (2025), against an average of $120.5 million.
• Across the five-year window, Assets Average tumbled 53.21% in 2023 and soared 97.88% in 2025, its largest moves.
• Xilio Therapeutics' Assets Average stood at $148.3 million in 2022, then sank by 53.21% to $69.4 million in 2023, then climbed by 5.02% to $72.9 million in 2024, then jumped by 97.88% to $144.2 million in 2025, then increased by 10.33% to $159.1 million in 2026.
• The last three Assets Average figures came in at $159.1 million (Q1 2026), $144.2 million (Q4 2025), and $133.8 million (Q3 2025), per Business Quant data.